AI filing briefs · archive

8-K filings in September 2024, explained

172 material Form 8-K filings that 152 companies we cover made with the SEC in September 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

2 of 172 briefs match

newest first · times in ET
SRESEMPRA Sep 13, 4:17 PM ET

Sempra EVP Trevor Mihalik to retire effective January 1, 2025

Neutral leadership Written later 5.02

Sempra said Executive Vice President and Group President Trevor I. Mihalik gave notice on September 10, 2024 that he will retire from that role effective January 1, 2025. He also steps down as non-executive Chairman and director of Southern California Gas Company, a Sempra subsidiary, on the same date. The filing does not name a successor or describe the reasons for the departure.

  • Trevor I. Mihalik gave notice of retirement on September 10, 2024.
  • Retirement is effective January 1, 2025, for his roles at Sempra.
  • He also leaves the non-executive Chairman and director posts at Southern California Gas Company on January 1, 2025.
  • The filing does not name a successor.
Read the filing on SEC.gov ↗
DVADAVITA INC. Sep 13, 4:15 PM ET

DaVita names David Maughan Chief Operating Officer, Kidney Care, effective September 15

Neutral leadership Written later 5.02

DaVita appointed Senior Vice President David P. Maughan as Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri, who moves to Chief Operating Officer Emeritus. The company also entered an employment agreement with Maughan with a $725,000 base salary and a 2024 target bonus of 100% of base salary.

  • David P. Maughan, 47, succeeds Michael D. Staffieri as COO, DaVita Kidney Care, effective September 15, 2024
  • Maughan joined DaVita in 2006 and most recently served as Senior Vice President, Kidney Care, from November 2019 to September 2024
  • Employment agreement sets annual base salary of $725,000 and a 2024 target incentive bonus equal to 100% of base salary
  • Severance includes at least one year of base salary continuation on resignation for good cause, or two years within 60 days after a good-cause event following a change in control
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.